In Gainesville, Biopharma Finds a Place in the Sun
Florida Region Has a Top-Tier Incubator, Recognized Schools, and Growing Companies
The Future Is Fluid
Liquid Biopsy Has Proven Its Mettle in the Fight against NSCLC and May Soon Also Be Standard of Care in Other Cancers
Genomics Brings Heavy Lifting to Immuno-Oncology
The Synergy of Two Burgeoning Fields Will Lead to Improved Precision Medicine
Singling Out RNA Biomarkers in Situ
ACD’s ISH Platform Achieves Single-Base Resolution and Retains Morphological Context
For full access to this article login to GEN Select now.
Fine-Tuning Cell-Based Assays
- Years of research and untold costs of development are wasted when a drug is withdrawn from the market. Pharmaceutical companies go to great lengths to prevent such loss, carrying out exhaustive studies from the preclinical phase through late-stage clinical trials to identify problems and eliminate them early. ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.